Survival Benefit Relative to Treatment Modalities Among Patients with Very Early Intrahepatic Cholangiocarcinoma: an Analysis of the National Cancer Database.
Intrahepatic cholangiocarcinoma
Liver resection
Liver transplantation
National Cancer Database
Non-curative-intent treatment
Journal
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
ISSN: 1873-4626
Titre abrégé: J Gastrointest Surg
Pays: Netherlands
ID NLM: 9706084
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
19
07
2023
accepted:
19
08
2023
medline:
14
2
2024
pubmed:
7
9
2023
entrez:
6
9
2023
Statut:
ppublish
Résumé
Liver transplantation (LT) has been considered a potential curative treatment for patients with very early intrahepatic cholangiocarcinoma (ICC) and cirrhosis, yet the survival benefit of LT has not been well defined. This study aimed to compare the long-term survival outcomes of patients who underwent LT with that of individuals who received resection and non-curative intent treatment (non-CIT). Patients who underwent LT, hepatectomy, and non-CIT between 2004 and 2018 were included in the National Cancer Database. Survival benefits of LT over resection and non-CIT were analyzed relative to overall survival (OS). Among 863 patients, 54 (6.3%) underwent LT, while 342 (39.6%) underwent surgical resection, and 467 (54.1%) received non-CIT, respectively. While the rates of non-CIT increased over time, the percentages of LT remained consistent during the study period. LT patients had similar 5-year OS to individuals who underwent resection (referent, resection: LT, HR 0.95, 95%CI 0.84-1.58, p=0.84). In contrast, 5-year OS was better among patients who underwent LT versus individuals who had non-CIT after controlling other variables using propensity score overlapping weighting (5-year OS, LT 57.1% vs. LR 25.8%, p<0.001). The outcomes of very early ICC patients who underwent LT were similar to individuals who underwent hepatectomy, but better than patients treated with non-CIT. LT should be may be a consideration as a treatment option for patients with early stage ICC who are unsuitable candidates for resection.
Sections du résumé
BACKGROUND
Liver transplantation (LT) has been considered a potential curative treatment for patients with very early intrahepatic cholangiocarcinoma (ICC) and cirrhosis, yet the survival benefit of LT has not been well defined. This study aimed to compare the long-term survival outcomes of patients who underwent LT with that of individuals who received resection and non-curative intent treatment (non-CIT).
METHODS
Patients who underwent LT, hepatectomy, and non-CIT between 2004 and 2018 were included in the National Cancer Database. Survival benefits of LT over resection and non-CIT were analyzed relative to overall survival (OS).
RESULTS
Among 863 patients, 54 (6.3%) underwent LT, while 342 (39.6%) underwent surgical resection, and 467 (54.1%) received non-CIT, respectively. While the rates of non-CIT increased over time, the percentages of LT remained consistent during the study period. LT patients had similar 5-year OS to individuals who underwent resection (referent, resection: LT, HR 0.95, 95%CI 0.84-1.58, p=0.84). In contrast, 5-year OS was better among patients who underwent LT versus individuals who had non-CIT after controlling other variables using propensity score overlapping weighting (5-year OS, LT 57.1% vs. LR 25.8%, p<0.001).
CONCLUSIONS
The outcomes of very early ICC patients who underwent LT were similar to individuals who underwent hepatectomy, but better than patients treated with non-CIT. LT should be may be a consideration as a treatment option for patients with early stage ICC who are unsuitable candidates for resection.
Identifiants
pubmed: 37674099
doi: 10.1007/s11605-023-05821-7
pii: S1091-255X(24)00111-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2103-2113Informations de copyright
© 2023. The Society for Surgery of the Alimentary Tract.
Références
Singal AK, Vauthey JN, Grady JJ, Stroehlein JR. Intra-hepatic cholangiocarcinoma--frequency and demographic patterns: thirty-year data from the M.D. Anderson Cancer Center. J Cancer Res Clin Oncol. 2011;137(7):1071-8. https://doi.org/10.1007/s00432-010-0971-z .
doi: 10.1007/s00432-010-0971-z
pubmed: 21207060
Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002;37(6):806-13. https://doi.org/10.1016/s0168-8278(02)00297-0 .
doi: 10.1016/s0168-8278(02)00297-0
pubmed: 12445422
Lima HA, Moazzam Z, Endo Y, Alaimo L, Diaz A, Woldesenbet S et al. Impact of the Affordable Care Act on Presentation, Treatment, and Outcomes of Intrahepatic Cholangiocarcinoma. J Gastrointest Surg. 2022. https://doi.org/10.1007/s11605-022-05496-6 .
Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol. 2012;57(1):69-76. https://doi.org/10.1016/j.jhep.2012.02.022 .
doi: 10.1016/j.jhep.2012.02.022
pubmed: 22420979
pmcid: 3804834
Kubo S, Shinkawa H, Asaoka Y, Ioka T, Igaki H, Izumi N et al. Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma. Liver Cancer. 2022;11(4):290-314. https://doi.org/10.1159/000522403 .
doi: 10.1159/000522403
pubmed: 35978598
pmcid: 9294959
de Jong MC, Nathan H, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29(23):3140-5. https://doi.org/10.1200/JCO.2011.35.6519 .
doi: 10.1200/JCO.2011.35.6519
pubmed: 21730269
Alaimo L, Endo Y, Lima HA, Moazzam Z, Shaikh CF, Ruzzenente A et al. A comprehensive preoperative predictive score for post-hepatectomy liver failure after hepatocellular carcinoma resection based on patient comorbidities, tumor burden, and liver function: the CTF score. J Gastrointest Surg. 2022;26:2486–95. https://doi.org/10.1007/s11605-022-05451-5 .
doi: 10.1007/s11605-022-05451-5
pubmed: 36100827
Thakral N, Gonzalez T, Nano O, Shin SH, Samuels S, Hussein A. Cirrhosis in intrahepatic cholangiocarcinoma: prognostic importance and impact on survival. BMC gastroenterology. 2023;23(1):151. https://doi.org/10.1186/s12876-023-02710-w .
doi: 10.1186/s12876-023-02710-w
pubmed: 37179301
pmcid: 10183123
Sapisochin G, Rodriguez de Lope C, Gastaca M, Ortiz de Urbina J, Suarez MA, Santoyo J et al. "Very early" intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients? Am J Transplant. 2014;14(3):660-7. https://doi.org/10.1111/ajt.12591 .
doi: 10.1111/ajt.12591
pubmed: 24410861
Eguchi S, Hidaka M, Hara T, Matsushima H, Soyama A. Liver transplantation for intrahepatic and hilar cholangiocellular carcinoma: Most recent updates in the literature. Ann Gastroenterol Surg. 2022;6(5):616-22. https://doi.org/10.1002/ags3.12567 .
doi: 10.1002/ags3.12567
pubmed: 36091305
pmcid: 9444854
Pichlmayr R, Weimann A, Tusch G, Schlitt HJ. Indications and Role of Liver Transplantation for Malignant Tumors. Oncologist. 1997;2(3):164-70.
doi: 10.1634/theoncologist.2-3-164
pubmed: 10388047
Hara T, Eguchi S, Yoshizumi T, Akamatsu N, Kaido T, Hamada T et al. Incidental intrahepatic cholangiocarcinoma in patients undergoing liver transplantation: A multi-center study in Japan. J Hepatobiliary Pancreat Sci. 2021;28(4):346-52. https://doi.org/10.1002/jhbp.896 .
doi: 10.1002/jhbp.896
pubmed: 33464720
Ziogas IA, Giannis D, Economopoulos KP, Hayat MH, Montenovo MI, Matsuoka LK et al. Liver Transplantation for Intrahepatic Cholangiocarcinoma: A Meta-analysis and Meta-regression of Survival Rates. Transplantation. 2021;105(10):2263-71. https://doi.org/10.1097/TP.0000000000003539 .
doi: 10.1097/TP.0000000000003539
pubmed: 33196623
Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10(1):35-43. https://doi.org/10.1016/s1470-2045(08)70284-5 .
doi: 10.1016/s1470-2045(08)70284-5
pubmed: 19058754
Hue JJ, Rocha FG, Ammori JB, Hardacre JM, Rothermel LD, Chavin KD et al. A comparison of surgical resection and liver transplantation in the treatment of intrahepatic cholangiocarcinoma in the era of modern chemotherapy: An analysis of the National Cancer Database. J Surg Oncol. 2021;123(4):949-56. https://doi.org/10.1002/jso.26370 .
doi: 10.1002/jso.26370
pubmed: 33400841
Lee YT, Singal AG, Lauzon M, Agopian VG, Luu M, Noureddin M et al. Disparities in curative treatments and outcomes for early stage intrahepatic cholangiocarcinoma in the United States. Cancer. 2022;128(20):3610-9. https://doi.org/10.1002/cncr.34436 .
doi: 10.1002/cncr.34436
pubmed: 35997126
De Martin E, Rayar M, Golse N, Dupeux M, Gelli M, Gnemmi V et al. Analysis of Liver Resection Versus Liver Transplantation on Outcome of Small Intrahepatic Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma in the Setting of Cirrhosis. Liver Transpl. 2020;26(6):785-98. https://doi.org/10.1002/lt.25737 .
doi: 10.1002/lt.25737
pubmed: 32090444
Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67(2):93-9. https://doi.org/10.3322/caac.21388 .
doi: 10.3322/caac.21388
pubmed: 28094848
Valle JW, Wasan H, Johnson P, Jones E, Dixon L, Swindell R et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. Br J Cancer. 2009;101(4):621-7. https://doi.org/10.1038/sj.bjc.6605211 .
doi: 10.1038/sj.bjc.6605211
pubmed: 19672264
pmcid: 2736816
Aalen OO. A linear regression model for the analysis of life times. Stat Med. 1989;8(8):907-25. https://doi.org/10.1002/sim.4780080803 .
doi: 10.1002/sim.4780080803
pubmed: 2678347
Hieke S, Kleber M, Konig C, Engelhardt M, Schumacher M. Conditional Survival: A Useful Concept to Provide Information on How Prognosis Evolves over Time. Clin Cancer Res. 2015;21(7):1530-6. https://doi.org/10.1158/1078-0432.CCR-14-2154 .
doi: 10.1158/1078-0432.CCR-14-2154
pubmed: 25833308
Li F, Thomas LE, Li F. Addressing Extreme Propensity Scores via the Overlap Weights. Am J Epidemiol. 2019;188(1):250-7. https://doi.org/10.1093/aje/kwy201 .
doi: 10.1093/aje/kwy201
pubmed: 30189042
Burnand B, Kernan WN, Feinstein AR. Indexes and boundaries for "quantitative significance" in statistical decisions. J Clin Epidemiol. 1990;43(12):1273-84. https://doi.org/10.1016/0895-4356(90)90093-5 .
doi: 10.1016/0895-4356(90)90093-5
pubmed: 2254764
Quaresima S, Melandro F, Giovanardi F, Shah K, De Peppo V, Mennini G et al. New Insights in the Setting of Transplant Oncology. Medicina (Kaunas). 2023;59(3). https://doi.org/10.3390/medicina59030568 .
Rosen CB, Heimbach JK, Gores GJ. Liver transplantation for cholangiocarcinoma. Transpl Int. 2010;23(7):692-7. https://doi.org/10.1111/j.1432-2277.2010.01108.x .
doi: 10.1111/j.1432-2277.2010.01108.x
pubmed: 20497401
Becker NS, Rodriguez JA, Barshes NR, O'Mahony CA, Goss JA, Aloia TA. Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period. J Gastrointest Surg. 2008;12(1):117-22. https://doi.org/10.1007/s11605-007-0335-4 .
doi: 10.1007/s11605-007-0335-4
pubmed: 17963015
Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao FY et al. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology. 2016;64(4):1178-88. https://doi.org/10.1002/hep.28744 .
doi: 10.1002/hep.28744
pubmed: 27481548
Sapisochin G, Ivanics T, Heimbach J. Liver Transplantation for Intrahepatic Cholangiocarcinoma: Ready for Prime Time? Hepatology. 2022;75(2):455-72. https://doi.org/10.1002/hep.32258 .
doi: 10.1002/hep.32258
pubmed: 34859465
Hong JC, Jones CM, Duffy JP, Petrowsky H, Farmer DG, French S et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch Surg. 2011;146(6):683-9. https://doi.org/10.1001/archsurg.2011.116 .
doi: 10.1001/archsurg.2011.116
pubmed: 21690444
Jesper D, Heyn SG, Schellhaas B, Pfeifer L, Goertz RS, Zopf S et al. Effects of liver cirrhosis and patient condition on clinical outcomes in intrahepatic cholangiocarcinoma: a retrospective analysis of 156 cases in a single center. Eur J Gastroenterol Hepatol. 2018;30(5):552-6. https://doi.org/10.1097/MEG.0000000000001036 .
doi: 10.1097/MEG.0000000000001036
pubmed: 29280922
Mauro E, Ferrer-Fabrega J, Sauri T, Soler A, Cobo A, Burrel M et al. New Challenges in the Management of Cholangiocarcinoma: The Role of Liver Transplantation, Locoregional Therapies, and Systemic Therapy. Cancers (Basel). 2023;15(4). https://doi.org/10.3390/cancers15041244 .
Endo Y, Sasaki K, Moazzam Z, Woldesenbet S, Yang J, Lima HA et al. The Impact of a Liver Transplant Program on the Outcomes of Hepatocellular Carcinoma. Ann Surg. 2023. https://doi.org/10.1097/SLA.0000000000005849 .
Flemming JA, Muaddi H, Djerboua M, Neves P, Sapisochin G, Selzner N. Association between social determinants of health and rates of liver transplantation in individuals with cirrhosis. Hepatology. 2022;76(4):1079-89. https://doi.org/10.1002/hep.32469 .
doi: 10.1002/hep.32469
pubmed: 35313040
Chan NW, Moya-Mendez M, Henson JB, Zaribafzadeh H, Sendak MP, Bhavsar NA et al. Social determinants of health data in solid organ transplantation: National data sources and future directions. Am J Transplant. 2022;22(10):2293-301. https://doi.org/10.1111/ajt.17096 .
doi: 10.1111/ajt.17096
pubmed: 35583111
pmcid: 9547872
Tovoli F, Guerra P, Iavarone M, Veronese L, Renzulli M, De Lorenzo S et al. Surveillance for Hepatocellular Carcinoma Also Improves Survival of Incidentally Detected Intrahepatic Cholangiocarcinoma Arisen in Liver Cirrhosis. Liver Cancer. 2020;9(6):744-55. https://doi.org/10.1159/000509059 .
doi: 10.1159/000509059
pubmed: 33442543
pmcid: 7768136
Weber SM, Ribero D, O'Reilly EM, Kokudo N, Miyazaki M, Pawlik TM. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB (Oxford). 2015;17(8):669-80. https://doi.org/10.1111/hpb.12441 .
doi: 10.1111/hpb.12441
pubmed: 26172134
pmcid: 4527852
Quillin RC, 3rd, Wilson GC, Wima K, Hohmann SF, Sutton JM, Shaw JJ et al. Neighborhood level effects of socioeconomic status on liver transplant selection and recipient survival. Clin Gastroenterol Hepatol. 2014;12(11):1934-41. https://doi.org/10.1016/j.cgh.2014.05.020 .
doi: 10.1016/j.cgh.2014.05.020
pubmed: 24907503
European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL-ILCA Clinical Practice Guidelines on Intrahepatic Cholangiocarcinoma. J Hepatol. 2023. https://doi.org/10.1016/j.jhep.2023.03.010 .
Biliary tract cancer. 2023. https://www.nccn.org/professionals/physician_gls/pdf/btc.pdf .
Simoneau E, D'Angelica M, Halazun KJ. Liver transplantation for colorectal liver metastasis. Curr Opin Organ Transplant. 2019;24(2):175-81. https://doi.org/10.1097/MOT.0000000000000623 .
doi: 10.1097/MOT.0000000000000623
pubmed: 30839338
Cross-Najafi AA, Lopez K, Isidan A, Park Y, Zhang W, Li P et al. Current Barriers to Clinical Liver Xenotransplantation. Front Immunol. 2022;13:827535. https://doi.org/10.3389/fimmu.2022.827535 .
doi: 10.3389/fimmu.2022.827535
pubmed: 35281047
pmcid: 8904558
Menahem B, Lubrano J, Duvoux C, Mulliri A, Alves A, Costentin C et al. Liver transplantation versus liver resection for hepatocellular carcinoma in intention to treat: An attempt to perform an ideal meta-analysis. Liver Transpl. 2017;23(6):836-44. https://doi.org/10.1002/lt.24758 .
doi: 10.1002/lt.24758
pubmed: 28295992